

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

19 September 2019 (19.09.2019)



(10) International Publication Number

WO 2019/175703 A1

(51) International Patent Classification:

A61K 9/10 (2006.01)

A61K 31/573 (2006.01)

A61K 47/38 (2006.01)

(21) International Application Number:

PCT/IB2019/051696

(22) International Filing Date:

03 March 2019 (03.03.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1803893.5

12 March 2018 (12.03.2018)

GB

(71) Applicant: SYRI LTD [GB/GB]; Unit 4, Bradfield Road, Ruislip, Middlesex HA4 0NU (GB).

(72) Inventors: PATEL, Kamlesh; Unit 4, Bradfield Road, Ruislip, Middlesex HA4 0NU (GB). PATEL, Sanjaykumar; No.3 - BP Estate, Opp. Sitaram Super Market, Chhani, Vadodara 391740 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: STABLE LIQUID SUSPENSION COMPOSITION OF FLUDROCORTISONE

(57) Abstract: The present invention relates to stable liquid suspension composition suitable for oral administration comprising fludrocortisone or pharmaceutically acceptable salts thereof and process for preparing the said liquid suspension pharmaceutical composition.



WO 2019/175703 A1


TITLE: STABLE LIQUID SUSPENSION COMPOSITION OF FLUDROCORTISONE

Field of the Invention

- 5 The present invention contemplates a stable liquid suspension composition of fludrocortisone or pharmaceutically acceptable salts thereof. The present invention contemplates more particularly a stable liquid composition of fludrocortisone or pharmaceutically acceptable salts thereof suitable for oral administration.

10 **Background of the Invention**

- Fludrocortisone (9-a-fluorocortisol): A synthetic analog of aldosterone that acts on the kidney so as to conserve sodium and excrete potassium. This definition includes derivatives of fludrocortisone, such as fludrocortisone acetate (which goes by the brand name Florinef®. Fludrocortisone in the form of its acetate salt has the chemical name 9-fluoro-11 β ,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate; its molecular formula is 15 C₂₃H₃₁FO₆, and its molecular weight is 422.493. The structural formula is shown below;



- 20 Fludrocortisone is prescribed for partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.

The usual dose is 0.1 mg of fludrocortisone acetate daily, although dosage ranging from 0.1 mg three times a week to 0.2 mg daily has been employed. In the event transient hypertension develops as a consequence of therapy, the dose should be reduced to 0.05 mg daily. Fludrocortisone acetate is preferably administered in conjunction with cortisone
5 (10 mg to 37.5 mg daily in divided doses) or hydrocortisone (10 mg to 30 mg daily in divided doses).

Products comprising fludrocortisone are marketed under the trade name FLORINEF®. Various tablet formulations of fludrocortisone have been approved for marketing, for
10 instance, conventional compressed instant release (IR) tablets comprising 0.1 mg of active ingredient. These are administered once, twice or three times daily.

In terms of pharmaceutical formulations, the major market is solid oral formulations or dosage forms because of ease of manufacturing, storage, stability etc. However on the
15 other hand, there are a huge number of patients who have difficulties swallowing, for example children and aged people. Also some patients with mental disorders or nauseated patients struggle with administration of such formulations. There are also certain situations when patients may be travelling and have very little or no access of water. In all such cases, the solid formulations appears to be non viable and may result in patient
20 non compliance and/or medication error. This may lead to discontinuation of medication. In absence of any oral liquid formulation available in the market, hospitals & dispensaries generally follow a practice of preparing extemporaneous suspensions from available solid formulations and triturating the same followed by adding water and, if required, syrup to make it palatable. For fludrocortisone such practice is followed by crushing commercially
25 available tablet formulation and mixing with water and syrup or some sweetener to prepare a palatable oral suspension for the patient.

However, the pharmacy practice of dispensing extemporaneous suspensions from solid formulations can create medication errors in terms of accurate dosing. This could lead to

potentially fatal conditions especially for a drug of this type which falls in low therapeutic index as in the case for fludrocortisone.

Thus the practice of dispensing extemporaneous suspensions of the drug is very unsafe
5 and may result in adverse effects.

Furthermore, preparing extemporaneous suspension may result in degradation of the active ingredients, if the active ingredient is sensitive to water or any other solvent exposure which may result in a decrease in concentration of the active ingredient in
10 extemporaneous suspension and patient may get less dose compared to the prescribed one for effective treatment.

To overcome these problems an oral liquid formulation is required.

In a liquid formulation, stability is the biggest challenge compared to solid formulations.
15 This is because in liquid formulations, the active ingredient will remain in a dissolved state in solvent vehicle (which is usually water or a medium comprised mostly of water) and water or the solvent medium is usually the reason for the instability. The solvent medium such as water may lead to degradation of the active ingredient. This is a potential issue for fludrocortisone.

20 Formation of foam during the preparation of liquid formulation is also a quite common problem and interfere with development of stable and effective liquid formulation. The severity of foam formation depends on nature of active ingredients as well as other excipients used in the preparation.

25 Still a need exists for stable liquid pharmaceutical composition of fludrocortisone which overcome all the problems discussed above. There is a need for oral administration formulations that do not have any stability or dose uniformity issue. Inventors of the present invention have addressed these issues and provided stable liquid pharmaceutical

composition suitable for oral administration comprising fludrocortisone or pharmaceutically acceptable salts thereof.

Summary of the Invention

- 5 The present invention relates a stable liquid suspension composition comprising fludrocortisone present in the range from 0.001 mg/ml to 1 mg/ml, a vehicle for fludrocortisone or salts thereof, a suspending agent, an anti foaming agent, at least one preservative and one or more inactive excipients.
- 10 In an embodiment, said stable liquid suspension composition comprises;
- a) 0.001 mg/ml to 1 mg/ml of fludrocortisone,
 - b) 0.01 to 5% w/v of a vehicle for fludrocortisone,
 - c) 0.1 to 10 % w/v of a suspending agent,
 - d) 0.005 to 1 % w/v of an anti-foaming agent,
 - 15 e) 0.008% w/v to 0.5% w/v of a preservative, and
 - f) one or more inactive excipients.

In certain embodiments, the stable liquid suspension composition comprises;

- g) 0.001 mg/ml to 1 mg/ml of fludrocortisone,
- 20 h) 0.01 to 5% w/v of glycerol,
- i) 0.1 to 10 % w/v of HPMC (hydroxypropyl methylcellulose) E4M,
- j) 0.005 to 1 % w/v of simethicone,
- k) methyl parahydroxybenzoate (methyl paraben) and ethyl parahydroxybenzoate (ethyl paraben),
- 25 l) one or more inactive excipients.

The stable liquid suspension is formulated in water or an aqueous medium including water.

One more aspect of the present invention is to provide process for preparing said stable liquid suspension composition comprising steps of;

- a) adding preservative in water and stirring,,
- b) adding a suspending agent to the solution of step a) optionally with continuous stirring,
- 5 c) adding antifoaming agent to the solution produced in step b), optionally with continuous stirring,
- d) adding sweetener to the solution produced in step c), optionally with continuous stirring,
- 10 e) dispersing fludrocortisone acetate in a mixture of vehicle and purified water,
- f) adding the dispersion produced in step e) in to the suspension produced in step d) to get an homogenous suspension, optionally with continuous stirring,
- g) adding buffering agent to the suspension produced in step f) to adjust the pH to from 3 to 5, and
- 15 h) adding purified water to make the final volume.

In any one or more of the above steps, where indicated as optional, continuous stirring may be employed in order to ensure good dissolution or suspension of the relevant component.

20

Detailed description of the Invention

Stable liquid pharmaceutical composition of fludrocortisone is the invention as further described herein.

- 25 The invention provides a stable liquid suspension composition comprising fludrocortisone present in the range from about 0.001 mg/ml to 1 mg/ml. The composition includes a vehicle for fludrocortisone, a suspending agent, an anti foaming agent, at least one preservative and one or more inactive excipients.

The term "pharmaceutically-acceptable salts" as used herein includes salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. Suitable pharmaceutically-acceptable acid addition salts of fludrocortisone may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, p-hydroxybenzoic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, alginic, β -hydroxybutyric, malonic, galactaric and galacturonic acid. The preferred salt form for the present invention is acetic and the Fludrocortisone is in the form of Fludrocortisone acetate.

The term "about" as and where used in this specification means $\pm 10\%$ of the mentioned value. However when the term "about" is used in connection with pH, it should be considered as ± 2 unit of the pH value.

The terms "formulation" and "composition" are intended to have the same meaning and are used interchangeably throughout this specification. The term "suspension" as used herein refers to a system in which small solid particles are essentially uniformly dispersed in a liquid medium.

The term "stable suspension", as used herein describes a suspension that shows no separation after being stored for at least 1 week at ambient temperature.

To keep liquid suspension composition of present invention stable for longer period of time, the pH also plays a role. It is typically necessary to carefully control the PH of the liquid suspension. As per one embodiment, pH of the composition should be from 3 to 5, preferably the pH is from 3.8 to 4.2, and ideally about 4.

The stable liquid suspension composition of the present invention is chemically and physically stable without any precipitation or crystallization. This was demonstrated in a stability study. Another benefit is that the composition overcame the problem of unpleasant taste.

5

A stable liquid suspension composition according to the present invention shows good stability and reproducibility even after long-term storage. This means that a liquid composition can be stored for a few days or a week or longer without significant degradation.

10

The stable liquid suspension composition of present invention, even though being in the form of a suspension also offers an advantage of uniform dosing, physical stability. It also reduces the chances of medication error or over dosage. The stable liquid suspension composition of the present invention, as described herein remains stable for longer period

15

Fludrocortisone acetate is a synthetic adrenocortical steroid possessing very potent mineralcorticoid properties and high glucocorticoid activity. It is used for its mineralcorticoid effects. It is a white to pale yellow, odourless or almost odourless, crystalline powder. Practically insoluble in water; soluble 1 in 50 in alcohol, 1 in 50 in chloroform; slightly soluble in ether.

20

As per one embodiment, fludrocortisone to be used in the form of Fludrocortisone acetate. The fludrocortisone acetate to be used in the range from 0.001 mg/ml to 1 mg/ml, preferably in the range from 0.005 mg/ml to 0.08 mg/ml, more preferably from 0.008 mg/ml to 0.05 mg/ml. In a most preferred embodiment, the fludrocortisone acetate is present in the range from 0.008 mg/ml to 0.02 mg/ml.

25

In certain embodiments, a stable liquid suspension composition comprises fludrocortisone present in the range from 0.001 mg/ml to 1 mg/ml, a vehicle for

30

fludrocortisone, a suspending agent, an anti foaming agent, at least one preservative and one or more inactive excipients. The liquid suspension is a suspension in water or a mixture of water and a co-solvent. Preferably, the liquid suspension is a suspension in water.

5

The stable liquid suspensions of the invention remain stable and uniform when appropriate excipients are selected and are used at specific and effective concentrations. One of the main excipients that plays role in stabilizing the pharmaceutical composition of present invention is suspending agent and vehicle for fludrocortisone or salts thereof.

10 As fludrocortisone is insoluble in water, an appropriate vehicle is required to disperse fludrocortisone acetate before preparing the final composition. Many vehicles are unsuitable for producing compositions of fludrocortisone. The inventors of the present invention tried many vehicles and surprisingly found that appropriate stability is observed when the vehicle is selected from one or more of: polyethylene glycol, glycerol and
15 propylene glycol. Further in a preferred embodiment, glycerol is used as a vehicle for dispersing fludrocortisone acetate. The amount of the vehicle for dispersing fludrocortisone acetate is used in the range from 0.01 to 5% w/v, and is preferably in the range from 0.05 to 1% w/v.

20 The suspending agent can be selected from one or more of: xanthan gum, guar gum, tragacanth gum, veegum, HPMC (hydroxypropyl methylcellulose), microcrystalline cellulose, Avicel RC-591 (microcrystalline cellulose/ sodium carboxymethyl cellulose), Carbopol® (carboxyvinyl polymer), polyvinyl Pyrrolidone.

25 In certain preferred embodiments, the suspending agent is cellulose based, in a preferred embodiment, HPMC (hydroxypropyl methylcellulose), microcrystalline cellulose or Avicel RC-591 (microcrystalline cellulose/ sodium carboxymethyl cellulose). As per more preferred embodiment, the suspending agent is HPMC (hydroxypropyl methylcellulose) also known as hypromellose.

30

Hypromellose is a solid, and is a slightly off-white to beige powder in appearance and may be formed into granules. The compound forms colloids when dissolved in water. This non-toxic ingredient is combustible and can react vigorously with oxidising agents. HPMC is available in different grades commercially based on the viscosity for the product
5 measured at 2% in water at 20°C. Different grades available are HPMC followed by K100 LV, K4M, K15M, K100M, E15 LV, E50 LV, E4M, F50 LV, F4M code. In a preferred embodiment, the HPMC with low viscosity grade are preferred, including HPMC K100LV, HPMCE4M, HPMC E50LV and HPMC E15LV. In a most preferred embodiment, the suspending agent is HPMC E4M.

10

The concentration of the suspending agent is also important. This impacts the final stability and physical characteristic of composition. As per one embodiment, the % of suspending agent is in the range from 0.1 to 10 % w/v, more preferably in the range from 0.25 to 5 % w/v and most preferred is 0.5 to 2.5 % w/v.

15

A substance used to reduce foam formation in liquid dosage compositions is called anti foaming agents also called as Defoamer. Commonly in process of manufacturing or when reconstituting of liquid dosage have this problem of foam formation forms needs it due to undesirable and disruptive Anti-foaming agents. These are effective to reduce foam by
20 lowering surface tension and cohesive binding of the liquid phase.

A defoamer or an anti-foaming agent is a chemical additive that reduces and hinders the formation of foam in industrial process liquids. The terms anti-foam agent and defoamer are often used interchangeably. Generally a defoamer is insoluble in the foaming
25 medium and has surface active properties. An essential feature of a defoamer product is a low viscosity and a facility to spread rapidly on foamy surfaces. It has affinity to the air-liquid surface where it destabilizes the foam lamellas. This causes rupture of the air bubbles and breakdown of surface foam. Entrained air bubbles are agglomerated, and the larger bubbles rise to the surface of the bulk liquid more quickly.

30

In certain embodiments, the anti-foaming agent for the present invention can be selected from one or more of: polydimethylsiloxane, simethicone, other silicones, stearates, alcohols and glycols. The anti-foaming agent may be of more than one of the above agents. In a preferred embodiment, the anti foaming agent is simethicone.

5

In an embodiment, the anti foaming agent is present in the range from 0.005 to 1 % w/v. In a preferred embodiment, anti foaming agent is present in the range from 0.01 to 0.5 % w/v. In a more preferred embodiment, anti foaming agent is present in the range from 0.01 to 0.1 % w/v. In a most embodiment, anti foaming agent is present in the range from

10 0.02 to 0.08 % w/v.

In certain embodiments, suitable preservative for present invention can be selected from one or more of: methyl parahydroxybenzoate (methyl paraben), ethyl parahydroxybenzoate (ethyl paraben), propyl parahydroxybenzoate (propyl paraben),

15 butyl parahydroxybenzoate (butyl paraben), isobutyl parahydroxybenzoate (isobutyl paraben), isopropyl parahydroxybenzoate (isopropyl paraben), benzyl parahydroxybenzoate (benzyl paraben), Sodium Benzoate, Benzoic acid, Potassium Sorbate and combinations thereof. In one embodiment the preservative is present in the range from about 0.001 %w/v to about 0.5 %w/v.

20

The present stable liquid suspension composition of present invention contains one or more inactive excipients selected from buffering agent, sweetener, anti oxidant, coloring agent and flavoring agent.

25 In certain embodiments, suitable buffer for present invention is selected from one or more of: Citric Acid monohydrate, Sodium Citrate, Sodium Dihydrogen Phosphate, Disodium Phosphate, Trometamol (Tris), Disodium hydrogen phosphate anhydrous, Hydrochloric Acid, Ascorbic Acid, Sodium Ascorbate and anhydrous, monohydrate or dehydrate forms thereof. The buffer can be single or any combination of above listed buffer. In a preferred

embodiment, combination of Disodium hydrogen phosphate anhydrous and Citric Acid monohydrate is to be used.

In certain embodiments, suitable sweetener for present invention is selected from one or
5 more of: acesulfame potassium, sucralose, cyclamate, saccharin, saccharin sodium and
aspartame or mixtures thereof. In a preferred embodiment, sucralose is to be used. The
liquid pharmaceutical composition of the present invention can be prepared in absence of
sweetener. However to make it more palatable and easily acceptable by patient especially
children, very small amount of sweetener can be added. Sweetener for the present
10 invention can be used in the range from about 0.01 %w/v to 0.5 % w/v.

In certain embodiments, the liquid pharmaceutical composition may further comprise anti
oxidants.

15 Suitable antioxidants for the composition of the present invention can be selected from
one or more of: consisting of butylated hydroxyanisole (BHA), butylated hydroxytoluene
(BHT), ascorbic acid, beta-carotene, alpha-tocopherol, propyl gallate, gentisic acid
sodium ascorbate, sodium bisulfite, sodium metabisulfite, monothioglycero, cysteine,
thioglycolate sodium, acetone sodium bisulfite, ascorbate (sodium/acid), bisulfite
20 sodium, cystein/cysteinat HCl, dithionite sodium (Na hydrosulfite, Na sulfoxylate),
gentisic acid, gentisic acid ethanolamine, glutamate monosodium, formaldehyde
sulfoxylate sodium, metabisulfite potassium, metabisulfite sodium, monothioglycerol
(thioglycerol), propyl gallate, sulfite sodium, tocopherol alpha and thioglycolate sodium.
The antioxidant may be a mixture of more than one of the above agents.

25

In certain embodiments the vehicle or solvent for making the final volume of the
composition can be selected from one or more of: glycerine, alcohols, propylene glycol,
polyethylene glycol, purified water, ethanol and isopropyl alcohol. The vehicle or solvent
may include mixtures of the above agents Preferably purified water is used as a solvent.

30

In one embodiment of the present invention, said stable liquid suspension composition comprises;

- a) 0.001 mg/ml to 1 mg/ml of fludrocortisone,
- b) vehicle for fludrocortisone or salts thereof,
- 5 c) a suspending agent,
- d) an anti foaming agent,
- e) at least one preservative and
- f) one or more inactive excipients.

- 10 The stable liquid composition of fludrocortisone is to be used for partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease. It can also be used for the treatment of salt-losing adrenogenital syndrome.

In another embodiment, said stable liquid suspension composition comprises;

- 15 a) 0.001 mg/ml to 1 mg/ml of fludrocortisone,
- b) vehicle for fludrocortisone or salts thereof selected from polyethylene glycol, glycerol and propylene glycol, or mixtures thereof,
- c) a suspending agent selected from xanthan gum, guar gum, tragacanth gum, veegum, HPMC (hydroxypropyl methylcellulose), microcrystalline cellulose,
- 20 Avicel RC-591 (microcrystalline cellulose/ sodium carboxymethyl cellulose), Carbopol® (carboxyvinyl polymer), polyvinyl Pyrrolidone, or mixtures thereof
- d) an anti foaming agent selected from polydimethylsiloxane, simethicone, other silicones, stearates, alcohols, glycols or combinations thereof,
- e) a preservative selected from methyl parahydroxybenzoate (methyl paraben), ethyl
- 25 parahydroxybenzoate (ethyl paraben), propyl parahydroxybenzoate (propyl paraben), butyl parahydroxybenzoate (butyl paraben), isobutyl parahydroxybenzoate (isobutyl paraben), isopropyl parahydroxybenzoate (isopropyl paraben), benzyl parahydroxybenzoate (benzyl paraben), Sodium Benzoate, Benzoic acid, Potassium Sorbate and combinations thereof, and
- 30 f) one or more inactive excipients.

In another embodiment, said stable liquid suspension composition comprises;

- a) 0.001 mg/ml to 1 mg/ml of fludrocortisone,
- b) 0.01 to 5% w/v of glycerol,
- 5 c) 0.1 to 10 % w/v of HPMC (hydroxypropyl methylcellulose) E4M,
- d) 0.005 to 1 % w/v of simethicone,
- e) methyl parahydroxybenzoate (methyl paraben) and ethyl parahydroxybenzoate (ethyl paraben),
- f) one or more inactive excipients.

10

In another embodiment, said stable liquid suspension composition comprises;

- a) 0.001 mg/ml to 1 mg/ml of fludrocortisone,
- b) 0.05 to 1% w/v of glycerol,
- c) 0.25 to 5 % w/v of HPMC (hydroxypropyl methylcellulose) E4M,
- 15 d) 0.01 to 0.5 % w/v of simethicone,
- e) methyl parahydroxybenzoate (methyl paraben) and ethyl parahydroxybenzoate (ethyl paraben),
- f) one or more inactive excipients.

20 In another embodiment, the stable liquid suspension composition is prepared by

- a) adding preservative in water and stirring,
- b) adding suspending agent in step a) with continuous stirring,
- c) adding antifoaming agent in step b) with continuous stirring,
- d) adding sweetener to step c) with continuous stirring,
- 25 e) dispersing fludrocortisone acetate in mixture of vehicle and purified water,
- f) adding dispersion of step e) in to step d) with continuous stirring to get homogenous suspension,
- g) adding buffering agent to step f) to adjust pH to from 3 to 5 and
- h) adding purified water to make final volume.

30

In another embodiment, the stable liquid suspension composition is prepared by

- a) adding methyl parahydroxybenzoate (methyl paraben) and ethyl parahydroxybenzoate (ethyl paraben) in water and stirring till dissolve it,
- b) adding HPMC (hydroxypropyl methylcellulose) E4M in step a) with continuous stirring,
- c) adding simethicone in step b) with continuous stirring,
- d) adding sucralose to step c) with continuous stirring,
- e) dispersing fludrocortisone acetate in mixture of glycerol and purified water,
- f) adding dispersion of step e) in to step d) with continuous stirring to get homogenous suspension,
- g) adding citric acid monohydrate and disodium hydrogen phosphate anhydrous to step f) to adjust pH in between 3 to 5 and
- h) adding purified water to make final volume.

- The invention is further illustrated by the following examples, which are by no means intended to limit the scope of the invention but are given by way of illustration.

Examples

Example 1: Fludrocortisone acetate Suspension 0.05 mg/5ml

Ingredients	gm/100ml
Fludrocortisone acetate	0.0010095*
Methyl parahydroxybenzoate	0.18
Ethyl parahydroxybenzoate	0.020
Simethicon PD30	0.060
HPMC E4M Premium	1.00
Sucralose	0.020
Glycerol	0.100
Caramel flavor	0.040
Citric acid monohydrate	Q.S. to pH 3 to 5

Disodium hydrogen phosphate anhydrous	Q.S. to pH 3 to 5
Purified water	Up to 100 ml

*value after potency correction as per COA.

Process:

1. Add and dissolve methyl parahydroxybenzoate and ethyl parahydroxybenzoate into 60
5 ml purified water with the aid of heating at above 90°C to get a clear, colourless solution. Keep aside till temperature reaches 60 -70°C.
2. Add HPMC E4M in step 1 when temperature reaches 60-70°C and keep aside to cool at room temperature.
3. Add simethicon PD30 and stir for 20- 30 minutes,
- 10 4. Add sucralose to step 3 and stir for 10-15 minutes using.
5. Separately disperse fludrocortisone acetate in glycerol and add 5ml of purified water and form uniform dispersion.
6. Add dispersion of step 5 into step 4 and mix to get homogeneous suspension.
7. Add citric acid monohydrate and disodium hydrogen phosphate anhydrous and mix to
15 get homogeneous suspension to adjust pH in between 3-5.
8. Add caramel flavor to suspension and mix it.
9. Make up to volume with purified water and stir for 10 minutes to get homogeneous suspension.

20 **Physical observations:** The composition of Example 1 was observed after storing for 24 hrs at room temperature. No any sedimentation or colour change observed, hence further stability studies at different temperature/humidity and time duration was planned.

25 **Example 2: Comparative examples**

	2A	2B	2C
--	----	----	----

Ingredients	gm/100ml	gm/100ml	gm/100ml
Fludrocortisone acetate	0.0010095*	0.0010095*	0.0010095*
Methyl parahydroxybenzoate	0.18	0.18	0.18
Ethyl parahydroxybenzoate	0.020	0.020	0.020
Simethicon PD30	0.060	0.060	0.060
Carmellose sodium (Cekol 2000 P)	1.00	-	0.25
Aluminium Mg Silicate (Veegm R)	-	1.00	0.50
Sucralose	0.020	0.020	0.020
Glycerol	0.100	0.100	0.100
Caramel flavor	0.040	0.040	0.040
Citric acid monohydrate	Q.S. to pH 3 to 5	Q.S. to pH 3 to 5	Q.S. to pH 3 to 5
Disodium hydrogen phosphate anhydrous	Q.S. to pH 3 to 5	Q.S. to pH 3 to 5	Q.S. to pH 3 to 5
Purified water	Up to 100 ml	Up to 100 ml	Up to 100 ml

Procedure: As per Example 1

Physical observations: The composition of Example 2 (2A, 2B and 2C) was observed after storing for 24 hrs at room temperature. There are sedimentation as well as slight color change was observed in all three composition. Therefore no further stability studies were conducted.

Example 3: Fludrocortisone acetate Suspension 0.05 mg/5ml

Ingredients	gm/100ml
Fludrocortisone acetate	0.0010095*
Methyl parahydroxybenzoate	0.20
Simethicon PD30	0.060

HPMC E15 LV	1.00
Sucralose	0.020
Propylene glycol	0.150
Caramel flavor	0.040
Citric acid monohydrate	Q.S. to pH 3 to 5
Disodium hydrogen phosphate anhydrous	Q.S. to pH 3 to 5
Purified water	Up to 100 ml

*value after potency correction as per COA.

Procedure: As per Example 1

Physical observations: The composition of Example 3 was observed after storing for 24 hrs at room temperature. There are very little sedimentation was observed but that was redispersible on shaking. No further stability conducted.

Example 4: Stability study of Example 1

Stability study of composition of Example 1 filled in amber colour glass bottle were performed at different temperature and relative humidity conditions for 6 months and results are as described below;

Results of stability study at 25°C/60%RH and 30°C/65%RH

Stability station	Initial	25°C/60%RH				30°C/65% RH
Storage condition	RT	1M	2M	3M	6M	6M
Description	Opaque white suspension					
pH	4.0	4.13	4.13	4.16	4.11	4.09

Assay (%w/w)	Fludrocortison e acetate (95.0% to 105.0%)	100.5%	100.2	98.3	94.6	93. 4	87
Assay (%w/w)	MHB (95.0% to 105.0%)	100.1%	100.5	99.9	99.6	97. 1	95.2
	EHB (95.0% to 105.0%)	97.4%	98.6	98.6	96.7	97. 6	95.5
Related substance s (%w/w)	Fludrocortison e : NMT 4.0%	0.171 (RRT:0.62 3)	0.600 (0.605)	1.70 7 (0.5 96)	2.54 6 (0.5 89)	5.2 97	7.301
	SMUI: NMT 1.0 %	0.122 (RRT: 0.851)	0.335 (0.861)	0.70 1 (0.8 52)	1.02 3 (0.8 46)	1.9 84	2.745
	Total Impurity	0.293	0.935	2.40 8	3.56 9	7.2 81	10.259
Dissolutio n Profile (Media: 0.01 N HCl, 500ml, 75 rpm, paddle)	45 Min	95.8	94.2	93.7	90.7	86. 9	87.6

Result of stability study at 2-8°C

Stability station	Initial	2-8°C
--------------------------	----------------	--------------

Storage condition		RT	1M	2M	3M	6M
Description		Opaque white suspension				
pH		4.0	4.18	4.2	4.04	4.12
Assay (%w/w)	Fludrocortisone acetate (95.0% to 105.0%)	100.5	100.2	99.7	98.4	98.0
	MHB (95.0% to 105.0%)	100.1	101.9	99.6	98.4	97.0
Assay (%w/w)	EHB (95.0% to 105.0%)	97.4	100.3	98.1	96.9	97.5
	Fludrocortisone : NMT 4.0%	0.171 (RRT:0.623)	0.213 (0.607)	0.448 (0.596)	0.537 (0.589)	1.245
Related substances (%w/w)	SMUI: NMT 1.0 %	0.122 (RRT: 0.851)	0.041 (0.865)	0.148 (0.853)	0.178 (0.846)	0.372
	Total Impurity	0.293	0.254	0.596	0.715	1.617
Dissolution Profile (Media: 0.01 N HCl, 500ml, 75 rpm, paddle)	45 Min	96.8	97.8	96.7	95.0	96.8

After performing stability study, it was observed that the liquid suspension composition of Example 1 shows good stability for 6 months storage when stored in the condition of 2-8°C.

Claims

1. A stable liquid suspension composition comprising fludrocortisone present in the range from about 0.001 mg/ml to 1 mg/ml, vehicle for fludrocortisone or salts thereof, a suspending agent, an anti foaming agent, at least one preservative and one or more inactive excipients.
2. The stable liquid suspension composition of claim 1, comprising:
0.001 mg/ml to 1 mg/ml of fludrocortisone,
0.01 to 5% w/v of a vehicle for fludrocortisone,
0.1 to 10 % w/v of a suspending agent,
0.005 to 1 % w/v of an anti-foaming agent,
a preservative, optionally in an amount of from 0.001% w/v to 0.5% w/v, and one or more inactive excipients.
3. The stable liquid suspension composition according to claim 1 or 2, wherein fludrocortisone is in the form of fludrocortisone acetate.
4. The stable liquid suspension composition according to any preceding claim, wherein the pH is in the range from about 3 to 5.
5. The stable liquid suspension composition according to any preceding claim, wherein liquid suspension is to be stored at condition of 2-8°C.
6. The stable liquid suspension composition according to any preceding claim, wherein vehicle for fludrocortisone is selected from polyethylene glycol, glycerol and propylene glycol.
7. The stable liquid suspension composition according to any preceding claim, wherein suspending agent is selected from xanthan gum, guar gum, tragacanth gum, veegum, HPMC (hydroxypropyl methylcellulose), microcrystalline cellulose, Avicel RC-591 (microcrystalline cellulose/ sodium carboxymethyl cellulose), Carbopol® (carboxyvinyl polymer) and polyvinyl Pyrrolidone.
8. The stable liquid suspension composition according to any preceding claim, wherein anti foaming agent is selected from polydimethylsiloxane, simethicone, other silicones, stearates, alcohols and glycols.

9. The stable liquid suspension composition according to any preceding claim, wherein preservative is selected from methyl parahydroxybenzoate (methyl paraben), ethyl parahydroxybenzoate (ethyl paraben), propyl parahydroxybenzoate (propyl paraben), butyl parahydroxybenzoate (butyl paraben), isobutyl parahydroxybenzoate (isobutyl paraben), isopropyl parahydroxybenzoate (isopropyl paraben), benzyl parahydroxybenzoate (benzyl paraben), Sodium Benzoate, Benzoic acid, Potassium Sorbate and combinations thereof
10. The stable liquid suspension composition according to any preceding claim, wherein inactive excipients is selected from buffering agent, sweetener, anti oxidant, coloring agent and flavoring agent.
11. The stable liquid suspension composition according to claim 10, wherein sweetener is selected from acesulfame potassium, sucralose, cyclamate, saccharin, saccharin sodium and aspartame or mixtures thereof.
12. The stable liquid suspension composition of claim 1, comprising;
- a) 0.001 mg/ml to 1 mg/ml of fludrocortisone,
 - b) 0.01 to 5% w/v of glycerol,
 - c) 0.1 to 10 % w/v of HPMC (hydroxypropyl methylcellulose) E4M,
 - d) 0.005 to 1 % w/v of simethicone,
 - e) methyl parahydroxybenzoate (methyl paraben) and ethyl parahydroxybenzoate (ethyl paraben),
 - f) one or more inactive excipients.
13. The stable liquid suspension composition of claim 1 comprising;
- a) 0.001 mg/ml to 1 mg/ml of fludrocortisone,
 - b) 0.05 to 1% w/v of glycerol,
 - c) 0.25 to 5 % w/v of HPMC (hydroxypropyl methylcellulose) E4M,
 - d) 0.01 to 0.5 % w/v of simethicone,
 - e) methyl parahydroxybenzoate (methyl paraben) and ethyl parahydroxybenzoate (ethyl paraben),

f) one or more inactive excipients.

14. A process for preparing a stable liquid suspension composition, comprising the steps of;

- 5 a) adding preservative in water and stirring till dissolve it,
- b) adding suspending agent in step a) with continuous stirring,
- c) adding antifoaming agent in step b) with continuous stirring,
- d) adding sweetener to step c) with continuous stirring,
- e) dispersing fludrocortisone acetate in mixture of vehicle and purified water,
- 10 f) adding dispersion of step e) in to step d) with continuous stirring to get homogenous suspension,
- g) adding buffering agent to step f) to adjust pH in between 3 to 5 and
- h) adding purified water to make final volume.

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2019/051696

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K9/10 A61K47/38 A61K31/573
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/039328 A2 (UNIV OREGON HEALTH & SCIENCE [US]; TRUNE DENNIS R [US]) 13 May 2004 (2004-05-13) the whole document	1-14
X	WO 2008/066899 A2 (MARINUS PHARMACEUTICALS [US]; SHAW KENNETH [US]; ZHANG MINGBAO [US]) 5 June 2008 (2008-06-05) the whole document	1-14
X	US 8 377 946 B1 (CHEN WEI [US] ET AL) 19 February 2013 (2013-02-19) the whole document	1-14
	----- -/--	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

4 June 2019

Date of mailing of the international search report

17/06/2019

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Giese, Hans-Hermann

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2019/051696

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2010/068775 A2 (AMIRA PHARMACEUTICALS INC [US]; HUTCHINSON JOHN HOWARD [US] ET AL.) 17 June 2010 (2010-06-17) the whole document paragraphs [0349], [0352] -----	1-14
X	WO 2015/127416 A1 (URIGEN PHARMACEUTICALS INC [US]; PARSONS C LOWELL [US] ET AL.) 27 August 2015 (2015-08-27) the whole document -----	1-14
A	WO 2007/062266 A2 (MARINUS PHARMACEUTICALS [US]; SHAW KENNETH [US]; ZHANG MINGBAO [US]) 31 May 2007 (2007-05-31) paragraph [0256]; claims -----	1-14
A	WO 2017/218894 A1 (CUTISPHARMA INC [US]) 21 December 2017 (2017-12-21) claims -----	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2019/051696

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004039328 A2	13-05-2004	AU 2003286792 A1 US 2006013858 A1 WO 2004039328 A2	25-05-2004 19-01-2006 13-05-2004
WO 2008066899 A2	05-06-2008	AU 2007325628 A1 BR PI0717721 A2 CA 2669815 A1 EP 2101735 A2 JP 2010510988 A KR 20090091321 A US 2009004262 A1 US 2011008453 A1 US 2013243830 A1 WO 2008066899 A2	05-06-2008 29-10-2013 05-06-2008 23-09-2009 08-04-2010 27-08-2009 01-01-2009 13-01-2011 19-09-2013 05-06-2008
US 8377946 B1	19-02-2013	US 8377946 B1 US 2013172314 A1 US 2015018336 A1 WO 2013102059 A1	19-02-2013 04-07-2013 15-01-2015 04-07-2013
WO 2010068775 A2	17-06-2010	US 2011301134 A1 WO 2010068775 A2	08-12-2011 17-06-2010
WO 2015127416 A1	27-08-2015	AU 2015218642 A1 CA 2949480 A1 CN 106456662 A EP 3110427 A1 JP 2017512757 A KR 20170003527 A US 2017189443 A1 WO 2015127416 A1	06-10-2016 27-08-2015 22-02-2017 04-01-2017 25-05-2017 09-01-2017 06-07-2017 27-08-2015
WO 2007062266 A2	31-05-2007	AP 3071 A AU 2006318349 A1 CA 2631233 A1 CN 101583620 A CN 106667918 A EA 200801468 A1 EP 1959966 A2 IL 191759 A JP 5334588 B2 JP 5748732 B2 JP 2009524582 A JP 2013064008 A KR 20080072760 A KR 20120107533 A KR 20130123471 A MX 336930 B NZ 568700 A US 2007141161 A1 US 2007148252 A1 US 2011236487 A1 US 2012052098 A1 US 2013156821 A1 US 2013287851 A1 US 2014154309 A1 US 2015313843 A1 US 2017202855 A1	31-12-2014 31-05-2007 31-05-2007 18-11-2009 17-05-2017 28-04-2009 27-08-2008 31-05-2015 06-11-2013 15-07-2015 02-07-2009 11-04-2013 06-08-2008 02-10-2012 12-11-2013 05-02-2016 30-03-2012 21-06-2007 28-06-2007 29-09-2011 01-03-2012 20-06-2013 31-10-2013 05-06-2014 05-11-2015 20-07-2017

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2019/051696

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 2019117673 A1	25-04-2019
		US 2019117674 A1	25-04-2019
		WO 2007062266 A2	31-05-2007

WO 2017218894 A1	21-12-2017	CA 3027434 A1	21-12-2017
		EP 3471725 A1	24-04-2019
		WO 2017218894 A1	21-12-2017
